Chemotherapy for advanced ovarian cancer

Stewart, Lesley

doi:10.1002/14651858.cd001418

Cited by 34 publications

(19 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is approved by the European Medicines Agency as a treatment for the first recurrence of platinum-sensitive EOC and for the management of various solid tumors in combination with cytotoxic chemotherapy [ 18 ]. Women who present with progression despite the platinum are considered platinum-refractory and present with the worst prognosis [ 19 ].…”

Section: Introductionmentioning

confidence: 99%

Markers of Oxidative Stress and Inflammation in Ascites and Plasma in Patients with Platinum‐Sensitive, Platinum‐Resistant, and Platinum‐Refractory Epithelial Ovarian Cancer

Cantón-Romero

Miranda-Díaz

Bañuelos-Ramírez

et al. 2017

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Diverse proinflammatory biomarkers and oxidative stress are strongly associated with advanced epithelial ovarian cancer (EOC). Objective. To determine the behavior of markers of oxidative stress and inflammation in plasma and ascites fluid in patients with platinum-sensitive, platinum-resistant, and platinum-refractory EOC. Methods. A prospective cohort study. The colorimetric method was used to determine levels of the markers 8-isoprostanes (8-IP), lipid peroxidation products (LPO), and total antioxidant capacity (TAC) in plasma and ascites fluid; and with ELISA, the levels of interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α) were determined in patients with EOC. Results. In ascites fluid, a significant increase in 8-IP versus baseline plasma levels was found (p = 0.002). There was an important leakage of the TAC levels in ascites fluid versus baseline plasma levels (p < 0.001). The IL-6 was elevated in ascites fluid versus baseline plasma levels (p = 0.003), and there were diminished levels of TNF-α in ascites fluid versus baseline plasma levels (p = 0.001). Discussion. We hypothesize that the ascites fluid influences the behavior and dissemination of the tumor. Deregulation between oxidants, antioxidants, and the proinflammatory cytokines was found to vary among platinum-sensitive, platinum-resistant, and platinum-refractory patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Markers of Oxidative Stress and Inflammation in Ascites and Plasma in Patients with Platinum‐Sensitive, Platinum‐Resistant, and Platinum‐Refractory Epithelial Ovarian Cancer

Cantón-Romero

Miranda-Díaz

Bañuelos-Ramírez

et al. 2017

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

show abstract

“…It has been suggested that a combination of taxane platinum-based chemotherapy regimens administered intravenously or intraperitoneally provides the best survival outcomes. 2 Despite this aggressive treatment program, most patients will develop chemoresistance and cancer recurrence within a few years of initial diagnosis. Multiple chemotherapeutic agents have been used in an attempt to treat patients with recurrence, but response rates are generally low (10%Y20%).…”

mentioning

confidence: 99%

Effect of TRA-8 Anti-Death Receptor 5 Antibody in Combination With Chemotherapy in an Ex Vivo Human Ovarian Cancer Model

Frederick

Kendrick

Straughn

et al. 2009

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

show abstract

“…15Y25 We assumed that docetaxel 26 and nab-paclitaxel were equivalent to paclitaxel in efficacy 27Y29 and that treatment with combination chemotherapy (platinum and taxane) had a mortality odds ratio of 0.91 (95% confidence interval [CI], 0.79Y1.05) compared to singleagent platinum. 30 The model was programmed using TreeAge Pro 2009 (TreeAge Software, Williamston, MA). For the base case, we assumed that patients were compliant with their medications as prescribed.…”

Section: Methodsmentioning

confidence: 99%

Intravenous Versus Oral Dexamethasone Premedication in Preventing Paclitaxel Infusion Hypersensitivity Reactions in Gynecological Malignancies

O’Cathail

Shaboodien²,

Mahmoud

et al. 2013

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

Chemotherapy for advanced ovarian cancer

Cited by 34 publications

References 42 publications

Markers of Oxidative Stress and Inflammation in Ascites and Plasma in Patients with Platinum‐Sensitive, Platinum‐Resistant, and Platinum‐Refractory Epithelial Ovarian Cancer

Markers of Oxidative Stress and Inflammation in Ascites and Plasma in Patients with Platinum‐Sensitive, Platinum‐Resistant, and Platinum‐Refractory Epithelial Ovarian Cancer

Effect of TRA-8 Anti-Death Receptor 5 Antibody in Combination With Chemotherapy in an Ex Vivo Human Ovarian Cancer Model

Intravenous Versus Oral Dexamethasone Premedication in Preventing Paclitaxel Infusion Hypersensitivity Reactions in Gynecological Malignancies

Contact Info

Product

Resources

About